Literature DB >> 35550115

Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.

Yuebo Zhang1, Yong Ma2, Ying Wang3, Debabrata Mukhopadhyay4, Yan Bi5, Baoan Ji6.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is notorious for high mortality due to limited options of appropriate chemotherapy drugs. Here we report that Aurora kinase-A expression is elevated in both human and mouse PDAC samples. MLN8237, an inhibitor of Aurora kinase-A, efficiently reduced the proliferation and motility of PDAC cells in vitro as well as tumor growth in orthotropic xenograft model and genetic pancreatic cancer animal models (p53/LSL/Pdx-Cre mice) in vivo. MLN8237 exhibited tumor inhibitory effect through inhibiting proliferation and migration, and inducing apoptosis and senescence. These results provide the molecular basis for a novel chemotherapy strategy for PDAC patients.
Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Aurora kinase; Pancreatic cancer; Senescence; Xenograft

Mesh:

Substances:

Year:  2022        PMID: 35550115      PMCID: PMC9189053          DOI: 10.1016/j.pan.2022.03.019

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.977


  41 in total

1.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

2.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Authors:  Fan Yang; Xiaoqing Guo; Gong Yang; Daniel G Rosen; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-03-25       Impact factor: 7.842

3.  Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73.

Authors:  Hiroshi Katayama; Jin Wang; Warapen Treekitkarnmongkol; Hidehiko Kawai; Kaori Sasai; Hui Zhang; Hua Wang; Henry P Adams; Shoulei Jiang; Sandip N Chakraborty; Fumio Suzuki; Ralph B Arlinghaus; Jinsong Liu; James A Mobley; William E Grizzle; Huamin Wang; Subrata Sen
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

4.  Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Authors:  Lifang Xie; Michelle Kassner; Ruben M Munoz; Qiang Q Que; Jeff Kiefer; Yu Zhao; Spyro Mousses; Hongwei H Yin; Daniel D Von Hoff; Haiyong Han
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

5.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Authors:  Paul M Barr; Hongli Li; Catherine Spier; Daruka Mahadevan; Michael LeBlanc; Mansoor Ul Haq; Bryan D Huber; Christopher R Flowers; Nina D Wagner-Johnston; Steven M Horwitz; Richard I Fisher; Bruce D Cheson; Sonali M Smith; Brad S Kahl; Nancy L Bartlett; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

6.  Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis.

Authors:  Thea M Goepfert; Yetunde E Adigun; Ling Zhong; Jason Gay; Daniel Medina; William R Brinkley
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Authors:  Shubha Anand; Sue Penrhyn-Lowe; Ashok R Venkitaraman
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

8.  Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians.

Authors:  Jinyun Chen; Donghui Li; Chongjuan Wei; Subrata Sen; Ann M Killary; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  Aurora kinase A inhibitor TCS7010 demonstrates pro-apoptotic effect through the unfolded protein response pathway in HCT116 colon cancer cells.

Authors:  Da Hyun Lee; Chang Gun Kim; Yoongho Lim; Soon Young Shin
Journal:  Oncol Lett       Date:  2017-09-22       Impact factor: 2.967

10.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.